ISCGX Mutual Fund

ISCGX Mutual Fund

NAV$5.10
See how much of ISCGX you already own
Just $25 once·$99/mo·Download sample
X-ray my portfolio free

Fund Essentials - as of Aug 31, 2026

Net Assets
$2M
Expense Ratio
1.10%
Dividend Yield (Current)
-
Holdings
64
Inception Date
Aug 31, 2012
Fund Family
Transamerica
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
SEC 30-Day Yield
PRO

Performance

YTD-1.17%
1 Year-0.21%
3 Year+7.06%
5 Year+1.78%
10 Year+10.41%

Asset Allocation

Stocks: 100.00%
See how much of ISCGX you already own
Your funds unpacked, overlap, fees and score, free on screen. The full report comes with FundXLS. Download sample.
X-ray my portfolio free

Top Holdings

View All →
TickerNameWeight
LGNDLigand Pharmaceuticals, Inc.4.42%
OIIOceaneering International Inc3.30%
CHYMChime Financial Inc Class A3.01%
EEExcelerate Energy, Inc.2.88%
HQYHealthequity Inc2.64%
Top 10 Concentration: 28.86%Report Date: Aug 31, 2026
Download all 64 holdings for ISCGX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Latest Distribution
$0.67
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

ISCGX Mutual Fund Overview

ISCGX Mutual Fund (Transamerica Small Cap Growth Fund Class I) is managed by Transamerica with $2.2M in net assets. ISCGX expense ratio is 1.10%, holding 64 positions across sectors including Industrials, Health Care, Information Technology. Inception date: 2012-08-31.

ISCGX performance shows a YTD return of -1.17%. The 1-year return is -0.21% and the 5-year return is 1.78%.

ISCGX top holdings include Ligand Pharmaceuticals, Inc. (4.4%), Oceaneering International Inc (3.3%), Chime Financial Inc Class A (3.0%), Excelerate Energy, Inc. (2.9%), Healthequity Inc (2.6%). Go to all ISCGX holdings, ISCGX sectors, or ISCGX dividends.

ISCGX can be compared against other funds. Use ISCGX overlap to find shared positions, or ISCGX vs another fund for a side-by-side view. ISCGX alternatives are available via the screener, along with tax-loss harvesting opportunities.